Results 51 to 60 of about 29,046 (192)

EARLY DISCONTINUATION OF FONDAPARINUX IN LOW-RISK PATIENTS HOSPITALIZED WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: MARKERS OF HEMOSTASIS ACTIVATION AND IN-HOSPITAL OUTCOMES

Российский кардиологический журнал, 2015
Current guidelines recommend use of anticoagulants (preferably fondaparinux) until hospital discharge in non-invasively treated patients (pts) with non-ST-segment elevation acute coronary syndrome (NSTEACS).
I. S. Yavelov, A. S. Knyazev, A. B. Dobrovolsky, N. A. Gratsiansky   +3 more
doaj   +1 more source

Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study

Frontiers in Medicine, 2020
Importance: The use of anticoagulant therapy with heparins decreased mortality in hospitalized patients with severe coronavirus disease 2019 (COVID-19). Even if enoxaparin and fondaparinux have the same clinical indication for venous thromboembolism (VTE)
Vincenzo Russo, Giuseppe Cardillo, Giuseppe Vito Viggiano, Sara Mangiacapra, Antonella Cavalli, Andrea Fontanella, Federica Agrusta, Annamaria Bellizzi, Maria Amitrano, Mariateresa Iannuzzo, Clara Sacco, Corrado Lodigiani, Giampiero Castaldo, Pierpaolo Di Micco   +13 more
doaj   +1 more source

Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage [PDF]

, 2017
Understanding of blood coagulation has evolved significantly in recent years. Both new coagulation proteins and inhibitors have been found and new interactions among previously known components of the coagulation system have been discovered.
Bombeli, T., Spahn, D. R.
core  

Anticoagulation therapy and proximal femoral fracture treatment: An update [PDF]

, 2016
Hip fractures in the elderly population have become a ‘disease’ with increasing incidence. Most of the geriatric patients are affected by a number of comorbidities.
Giannoudis, PV, Giannoudis, V, Ktistakis, I   +2 more
core   +2 more sources

Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data

Arquivos Brasileiros de Cardiologia, 2016
Background: Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction.
Alexandre de Matos Soeiro, Pedro Gabriel Melo de Barros e Silva, Eduardo Alberto de Castro Roque, Aline Siqueira Bossa, Maria Cristina César, Sheila Aparecida Simões, Mariana Yumi Okada, Tatiana de Carvalho Andreucci Torres Leal, Fátima Cristina Monteiro Pedroti, Múcio Tavares de Oliveira Jr.   +9 more
doaj   +1 more source

Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)

Frontiers in Pharmacology
Background: Thromboembolic disease is associated with a high rate of disability or death and gravely jeopardizes people’s health and places considerable financial pressure on society.
Qinan Yin, Qinan Yin, Lizhu Han, Lizhu Han, Yin Wang, Fengjiao Kang, Fengqun Cai, Liuyun Wu, Xingyue Zheng, Lian Li, Li e Dong, Limei Dong, Shuhong Liang, Min Chen, Min Chen, Yong Yang, Yong Yang, Yuan Bian, Yuan Bian   +18 more
doaj   +1 more source

Clinical experience with fondaparinux in antiaggregate patients undergoing total hip and knee arthroplasty

Italian Journal of Medicine, 2013
Patients undergoing total hip arthroplasty or total knee arthroplasty have a high risk for post-operative venous thromboembolism. The current study addressed the use of fondaparinux post-operatively in 556 patients with antiplatelet therapy in order to ...
Guido Grappiolo, Marco Scardino, Giuseppe Mazziotta, Stefano Quaini, Corrado Lodigiani, Matteo Carlo Ferrari   +5 more
doaj   +1 more source

Fondaparinux in the management of patients with ST-elevation acute myocardial infarction

Vascular Health and Risk Management, 2006
Alexander GG TurpieHamilton Health Sciences Corporation – General Division, Hamilton, ON, CanadaAbstract: The death rate of patients with ST-segment elevation myocardial infarction (STEMI) remains substantial.
Alexander GG Turpie
doaj  

Cibles des médicaments antithrombotiques [PDF]

, 2006
Pour la quasi-totalité des classes thérapeutiques antithrombotiques actuellement utilisées et à venir, le ciblage a été initialement la conséquence d’une observation et non pas le fruit d’une recherche méthodique scientifique.
Drouet, Ludovic, Ripoll, Laurent
core   +1 more source

Management of acute coronary syndromes with fondaparinux

Vascular Health and Risk Management, 2007
Harm Wienbergen, Uwe ZeymerHerzzentrum Ludwigshafen, Medizinische Klinik B, GermanyAbstract: Fondaparinux is the first selective inhibitor of the coagulation factor Xa which is commercially avaliable for clinical use.
Harm Wienbergen, Uwe Zeymer
doaj